Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide-based neoadjuvant/induction therapy for locally advanced or oligometastatic hormone-sensitive prostate cancer
ChiCTR2500096436Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Jan 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of darolutamide in prostate cancer (PCa), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoints: Pathological complete remission rate and Minimal residual disease rate. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2500096436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096436.